Abstract
Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P
Original language | English |
---|---|
Pages (from-to) | 1402-1406 |
Number of pages | 5 |
Journal | European Journal of Neurology |
Volume | 18 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2011 |
Keywords
- Case-control study
- Insulin-like growth factor-binding protein-3
- Insulin-like growth factor-I
- Multiple sclerosis
- Relapsing-remitting
- Secondary progressive
ASJC Scopus subject areas
- Clinical Neurology
- Neurology